+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis



Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis



Core Evidence 5: 107-112



Dalfampridine sustained-release (SR) is a time-release formulation of 4-aminopyridine, recently approved by the Food and Drug Administration to improve walking in patients with multiple sclerosis (MS). In Phase II trials, walking speed and lower extremity muscle strength was increased in patients with MS, but the increase in walking speed did not reach statistical significance. A responder analysis revealed that approximately 35% of treated patients had a statistically significant and clinically meaningful increase in walking speed. When treated responders were compared with treated nonresponders, walking speed significantly increased in the responder group, but not in the nonresponder or placebo groups. This result was duplicated in two larger Phase III trials. The optimal dose to maximize the risk-benefit ratio was 10 mg twice daily. Higher doses were associated with a greater risk of seizure, but no further improvement in walking speed or in the proportion of responders. Dalfampridine SR is eliminated by renal clearance and undergoes only limited metabolism (<10%). It is contraindicated in patients with moderate or severe renal insufficiency and in those with a history of seizures or epileptiform activity on electroencephalography. The development of time-released 4-aminopyridine represents a major advance in symptomatic therapy for MS.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052445726

Download citation: RISBibTeXText

PMID: 21468366

DOI: 10.2147/CE.S9046


Related references

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis. Neuropsychiatric Disease and Treatment 7: 229-239, 2011

Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study. Multiple Sclerosis 20(6): 733-738, 2015

Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis. International Journal of Ms Care 17(6): 275-283, 2015

Walking impairment in patients with multiple sclerosis - a new therapeutic approach and clinical potential of dalfampridine extended release tablets. Degenerative Neurological and Neuromuscular Disease 2: 53-64, 2019

Extended-release dalfampridine in the management of multiple-sclerosis-related walking impairment. Therapeutic Advances in Neurological Disorders 5(4): 199-204, 2012

Dalfampridine: a medication to improve walking in patients with multiple sclerosis. Annals of PharmacoTherapy 46(7-8): 1010-1015, 2012

Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Current Medical Research and Opinion 27(7): 1415-1423, 2011

Treatment of walking impairment in multiple sclerosis with dalfampridine. Therapeutic Advances in Neurological Disorders 4(2): 99-109, 2011

Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis. Current Medical Research and Opinion 29(12): 1627-1636, 2014

Dalfampridine in multiple sclerosis: from symptomatic treatment to immunomodulation. Clinical Immunology 142(1): 84-92, 2012

Dalfampridine: a new agent for symptomatic management of multiple sclerosis. American Journal of Health-System Pharmacy 68(24): 2335-2340, 2012

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials. Multiple Sclerosis 21(10): 1322-1331, 2016

Walking speed and economic outcomes for walking-impaired patients with multiple sclerosis. Expert Review of Pharmacoeconomics and Outcomes Research 10(5): 595-603, 2011

Relations between 6 minute walking distance and 10 meter walking speed in patients with multiple sclerosis and stroke. Archives of Physical Medicine and Rehabilitation 93(7): 1167-1172, 2012

Sustained-release fampridine for symptomatic treatment of multiple sclerosis. Annals of PharmacoTherapy 42(10): 1458-1465, 2008